Natera

Company profile

About Natera

Natera is a global leader in cell-free DNA (cfDNA) testing and molecular diagnostics, serving patients and clinicians across oncology, women's health, organ health, and rare disease. The company's mission is to advance molecular diagnostics with integrity and scientific rigor, supporting the integration of test information into healthcare decision-making to enable more personalized care. Natera's technology platform measures fetal, tumor, or donor cfDNA at the molecular level through noninvasive testing. In oncology, products include Signatera™ for residual disease monitoring (MRD), Latitude™ for tissue-free MRD, Altera™ for tumor genomic profiling, and Empower™ for hereditary cancer screening. In organ health, Prospera™ tests assess kidney, heart, and lung transplant rejection, while Renasight™ provides kidney gene panel testing. Women's health offerings include Horizon™ carrier screening, Panorama™ noninvasive prenatal testing (NIPT), Vistara™ single-gene NIPT, and Anora™ miscarriage testing. The rare disease portfolio features Zenith™ genomic testing. Natera's tests are clinically validated in over 400 peer-reviewed publications with over 3 million patients studied. The company has participated in major prospective studies including CIRCULATE (oncology), SMART (women's health), and Trifecta (organ health). With over 16 million tests processed in CAP/CLIA-certified laboratories and more than 150 medical professionals on staff, Natera delivers high-quality molecular diagnostic results that help clinicians make more informed treatment decisions and enable earlier, more targeted interventions.

Company description · Natera official website